ID   FHIT_HUMAN              Reviewed;         147 AA.
AC   P49789; A2IAS9; A2IAT0; A2IAT6; A8K1A9; Q45QG9; Q6IU12;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   15-MAR-2017, entry version 162.
DE   RecName: Full=Bis(5'-adenosyl)-triphosphatase;
DE            EC=3.6.1.29;
DE   AltName: Full=AP3A hydrolase;
DE            Short=AP3Aase;
DE   AltName: Full=Diadenosine 5',5'''-P1,P3-triphosphate hydrolase;
DE   AltName: Full=Dinucleosidetriphosphatase;
DE   AltName: Full=Fragile histidine triad protein;
GN   Name=FHIT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=8598045; DOI=10.1016/S0092-8674(00)81034-X;
RA   Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J.,
RA   Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., Huebner K.;
RT   "The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal
RT   carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract
RT   cancers.";
RL   Cell 84:587-597(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9012482;
RA   Druck T., Hadaczek P., Fu T.B., Ohta M., Siprashvili Z., Baffa R.,
RA   Negrini M., Kastury K., Veronese M.L., Rosen D., Rothstein J.,
RA   McCue P., Cotticelli M.G., Inoue H., Croce C.M., Huebner K.;
RT   "Structure and expression of the human FHIT gene in normal and tumor
RT   cells.";
RL   Cancer Res. 57:504-512(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=24722188; DOI=10.1038/ncomms4650;
RA   Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L.,
RA   Broly M., Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S.,
RA   Tasan M., Lemmens I., Kuang X., Zhao N., Malhotra D., Michaelson J.J.,
RA   Vacic V., Calderwood M.A., Roth F.P., Tavernier J., Horvath S.,
RA   Salehi-Ashtiani K., Korkin D., Sebat J., Hill D.E., Hao T., Vidal M.,
RA   Iakoucheva L.M.;
RT   "Protein interaction network of alternatively spliced isoforms from
RT   brain links genetic risk factors for autism.";
RL   Nat. Commun. 5:3650-3650(2014).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF
RP   94-146.
RA   Naqvi S.R.A., Malik A., Kukreti H., Chaudhary A., Anand R., Deo S.S.,
RA   Shukla N.K., Husain S.A., Pasha S.T.;
RT   "Mutational analysis of FHIT gene.";
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-35; HIS-94;
RP   HIS-96 AND HIS-98.
RX   PubMed=8794732; DOI=10.1021/bi961415t;
RA   Barnes L.D., Garrison P.N., Siprashvili Z., Guranowski A.,
RA   Robinson A.K., Ingram S.W., Croce C.M., Ohta M., Huebner K.;
RT   "Fhit, a putative tumor suppressor in humans, is a dinucleoside
RT   5',5''-P1,P3-triphosphate hydrolase.";
RL   Biochemistry 35:11529-11535(1996).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH RNF139.
RX   PubMed=9689122; DOI=10.1073/pnas.95.16.9572;
RA   Gemmill R.M., West J.D., Boldog F., Tanaka N., Robinson L.J.,
RA   Smith D.I., Li F., Drabkin H.A.;
RT   "The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a
RT   patched-related gene, TRC8.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9572-9577(1998).
RN   [10]
RP   INTERACTION WITH UBE2I.
RX   PubMed=11085938; DOI=10.1042/bj3520443;
RA   Shi Y., Zou M., Farid N.R., Paterson M.C.;
RT   "Association of FHIT (fragile histidine triad), a candidate tumour
RT   suppressor gene, with the ubiquitin-conjugating enzyme hUBC9.";
RL   Biochem. J. 352:443-448(2000).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ILE-10; LEU-25 AND
RP   HIS-96.
RX   PubMed=12574506; DOI=10.1073/pnas.0437915100;
RA   Trapasso F., Krakowiak A., Cesari R., Arkles J., Yendamuri S.,
RA   Ishii H., Vecchione A., Kuroki T., Bieganowski P., Pace H.C.,
RA   Huebner K., Croce C.M., Brenner C.;
RT   "Designed FHIT alleles establish that Fhit-induced apoptosis in cancer
RT   cells is limited by substrate binding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:1592-1597(2003).
RN   [12]
RP   ACTIVE SITE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-96.
RX   PubMed=15182206; DOI=10.1021/bi049762n;
RA   Huang K., Arabshahi A., Wei Y., Frey P.A.;
RT   "The mechanism of action of the fragile histidine triad, Fhit:
RT   isolation of a covalent adenylyl enzyme and chemical rescue of H96G-
RT   Fhit.";
RL   Biochemistry 43:7637-7642(2004).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MDM2.
RX   PubMed=15313915; DOI=10.1158/0008-5472.CAN-04-0195;
RA   Nishizaki M., Sasaki J., Fang B., Atkinson E.N., Minna J.D.,
RA   Roth J.A., Ji L.;
RT   "Synergistic tumor suppression by coexpression of FHIT and p53
RT   coincides with FHIT-mediated MDM2 inactivation and p53 stabilization
RT   in human non-small cell lung cancer cells.";
RL   Cancer Res. 64:5745-5752(2004).
RN   [14]
RP   PHOSPHORYLATION BY SRC, SUBUNIT, SUBCELLULAR LOCATION, MASS
RP   SPECTROMETRY, DISEASE, PHOSPHORYLATION AT TYR-114 AND TYR-145, AND
RP   MUTAGENESIS OF TYR-114 AND TYR-145.
RX   PubMed=15007172; DOI=10.1073/pnas.0400481101;
RA   Pekarsky Y., Garrison P.N., Palamarchuk A., Zanesi N., Aqeilan R.I.,
RA   Huebner K., Barnes L.D., Croce C.M.;
RT   "Fhit is a physiological target of the protein kinase Src.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3775-3779(2004).
RN   [15]
RP   MUTAGENESIS OF TYR-114, AND FUNCTION.
RX   PubMed=16407838; DOI=10.1038/sj.onc.1209323;
RA   Semba S., Trapasso F., Fabbri M., McCorkell K.A., Volinia S.,
RA   Druck T., Iliopoulos D., Pekarsky Y., Ishii H., Garrison P.N.,
RA   Barnes L.D., Croce C.M., Huebner K.;
RT   "Fhit modulation of the Akt-survivin pathway in lung cancer cells:
RT   Fhit-tyrosine 114 (Y114) is essential.";
RL   Oncogene 25:2860-2872(2006).
RN   [16]
RP   INTERACTION WITH CTNNB1, IDENTIFICATION IN A COMPLEX WITH CTNNB1 AND
RP   LEF1, AND FUNCTION.
RX   PubMed=18077326; DOI=10.1073/pnas.0703664105;
RA   Weiske J., Albring K.F., Huber O.;
RT   "The tumor suppressor Fhit acts as a repressor of beta-catenin
RT   transcriptional activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:20344-20349(2007).
RN   [17]
RP   SUBCELLULAR LOCATION, AND FUNCTION IN APOPTOSIS.
RX   PubMed=19622739; DOI=10.1073/pnas.0906484106;
RA   Rimessi A., Marchi S., Fotino C., Romagnoli A., Huebner K.,
RA   Croce C.M., Pinton P., Rizzuto R.;
RT   "Intramitochondrial calcium regulation by the FHIT gene product
RT   sensitizes to apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:12753-12758(2009).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS).
RX   PubMed=9261067; DOI=10.1016/S0969-2126(97)00231-1;
RA   Lima C.D., D'Amico K.L., Naday I., Rosenbaum G., Westbrook E.M.,
RA   Hendrickson W.A.;
RT   "MAD analysis of FHIT, a putative human tumor suppressor from the HIT
RT   protein family.";
RL   Structure 5:763-774(1997).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) IN COMPLEXES WITH SUBSTRATES,
RP   CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, AND ACTIVE SITE.
RX   PubMed=9323207; DOI=10.1126/science.278.5336.286;
RA   Lima C.D., Klein M.G., Hendrickson W.A.;
RT   "Structure-based analysis of catalysis and substrate definition in the
RT   HIT protein family.";
RL   Science 278:286-290(1997).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) IN COMPLEXES WITH SUBSTRATE
RP   ANALOGS, SUBUNIT, CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-96.
RX   PubMed=9576908; DOI=10.1073/pnas.95.10.5484;
RA   Pace H.C., Garrison P.N., Robinson A.K., Barnes L.D., Draganescu A.,
RA   Roesler A., Blackburn G.M., Siprashvili Z., Croce C.M., Huebner K.,
RA   Brenner C.;
RT   "Genetic, biochemical, and crystallographic characterization of Fhit-
RT   substrate complexes as the active signaling form of Fhit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:5484-5489(1998).
CC   -!- FUNCTION: Cleaves P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap3A)
CC       to yield AMP and ADP. Can also hydrolyze P(1)-P(4)-bis(5'-
CC       adenosyl) tetraphosphate (Ap4A), but has extremely low activity
CC       with ATP. Modulates transcriptional activation by CTNNB1 and
CC       thereby contributes to regulate the expression of genes essential
CC       for cell proliferation and survival, such as CCND1 and BIRC5.
CC       Plays a role in the induction of apoptosis via SRC and AKT1
CC       signaling pathways. Inhibits MDM2-mediated proteasomal degradation
CC       of p53/TP53 and thereby plays a role in p53/TP53-mediated
CC       apoptosis. Induction of apoptosis depends on the ability of FHIT
CC       to bind P(1)-P(3)-bis(5'-adenosyl) triphosphate or related
CC       compounds, but does not require its catalytic activity, it may in
CC       part come from the mitochondrial form, which sensitizes the low-
CC       affinity Ca(2+) transporters, enhancing mitochondrial calcium
CC       uptake. Functions as tumor suppressor.
CC       {ECO:0000269|PubMed:12574506, ECO:0000269|PubMed:15313915,
CC       ECO:0000269|PubMed:16407838, ECO:0000269|PubMed:18077326,
CC       ECO:0000269|PubMed:19622739, ECO:0000269|PubMed:8794732,
CC       ECO:0000269|PubMed:9323207}.
CC   -!- CATALYTIC ACTIVITY: P(1)-P(3)-bis(5'-adenosyl) triphosphate +
CC       H(2)O = ADP + AMP. {ECO:0000269|PubMed:12574506,
CC       ECO:0000269|PubMed:15182206, ECO:0000269|PubMed:8794732,
CC       ECO:0000269|PubMed:9323207, ECO:0000269|PubMed:9576908}.
CC   -!- SUBUNIT: Homodimer. Interacts with UBE2I. Interacts with MDM2.
CC       Interacts with CTNNB1. Identified in a complex with CTNNB1 and
CC       LEF1. {ECO:0000269|PubMed:11085938, ECO:0000269|PubMed:15007172,
CC       ECO:0000269|PubMed:15313915, ECO:0000269|PubMed:18077326,
CC       ECO:0000269|PubMed:9323207, ECO:0000269|PubMed:9576908}.
CC   -!- INTERACTION:
CC       Self; NbExp=8; IntAct=EBI-741760, EBI-741760;
CC       P22570:FDXR; NbExp=4; IntAct=EBI-741760, EBI-1751533;
CC       P10809:HSPD1; NbExp=5; IntAct=EBI-741760, EBI-352528;
CC       P61604:HSPE1; NbExp=4; IntAct=EBI-741760, EBI-711483;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Mitochondrion. Nucleus.
CC   -!- TISSUE SPECIFICITY: Low levels expressed in all tissues tested.
CC       Phospho-FHIT observed in liver and kidney, but not in brain and
CC       lung. Phospho-FHIT undetected in all tested human tumor cell
CC       lines.
CC   -!- PTM: Phosphorylation at Tyr-114 by SRC is required for induction
CC       of apoptosis. {ECO:0000269|PubMed:15007172}.
CC   -!- MASS SPECTROMETRY: Mass=16733; Method=MALDI; Range=2-147;
CC       Evidence={ECO:0000269|PubMed:15007172};
CC   -!- DISEASE: Note=A chromosomal aberration involving FHIT has been
CC       found in a lymphoblastoid cell line established from a family with
CC       renal cell carcinoma and thyroid carcinoma. Translocation
CC       t(3;8)(p14.2;q24.1) with RNF139. Although the 3p14.2 breakpoint
CC       has been shown to interrupt FHIT in its 5-prime non-coding region,
CC       it is unlikely that FHIT is causally related to renal or other
CC       malignancies. {ECO:0000269|PubMed:15007172}.
CC   -!- DISEASE: Note=Associated with digestive tract cancers. Numerous
CC       tumor types are found to have aberrant forms of FHIT protein due
CC       to deletions in a coding region of chromosome 3p14.2 including the
CC       fragile site locus FRA3B. {ECO:0000269|PubMed:15007172}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FHITID192ch3p14.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U46922; AAA99013.1; -; mRNA.
DR   EMBL; U76271; AAB52539.1; -; Genomic_DNA.
DR   EMBL; U76267; AAB52539.1; JOINED; Genomic_DNA.
DR   EMBL; U76268; AAB52539.1; JOINED; Genomic_DNA.
DR   EMBL; U76269; AAB52539.1; JOINED; Genomic_DNA.
DR   EMBL; U76270; AAB52539.1; JOINED; Genomic_DNA.
DR   EMBL; KJ534835; AHW56475.1; -; mRNA.
DR   EMBL; AY625256; AAT37530.1; -; Genomic_DNA.
DR   EMBL; DQ120721; AAZ23623.1; -; mRNA.
DR   EMBL; EF186677; ABM65879.1; -; Genomic_DNA.
DR   EMBL; EF183457; ABM66086.1; -; Genomic_DNA.
DR   EMBL; EF183458; ABM66087.1; -; Genomic_DNA.
DR   EMBL; EF183459; ABM66088.1; -; Genomic_DNA.
DR   EMBL; EF183461; ABM66090.1; -; Genomic_DNA.
DR   EMBL; EF183464; ABM66093.1; -; Genomic_DNA.
DR   EMBL; AK289824; BAF82513.1; -; mRNA.
DR   EMBL; CH471055; EAW65393.1; -; Genomic_DNA.
DR   EMBL; BC032336; AAH32336.1; -; mRNA.
DR   CCDS; CCDS2894.1; -.
DR   PIR; A58802; A58802.
DR   RefSeq; NP_001159715.1; NM_001166243.2.
DR   RefSeq; NP_001307828.1; NM_001320899.1.
DR   RefSeq; NP_001307829.1; NM_001320900.1.
DR   RefSeq; NP_002003.1; NM_002012.3.
DR   UniGene; Hs.655995; -.
DR   PDB; 1FHI; X-ray; 3.10 A; A=1-147.
DR   PDB; 1FIT; X-ray; 1.85 A; A=1-147.
DR   PDB; 2FHI; X-ray; 2.60 A; A=1-147.
DR   PDB; 2FIT; X-ray; 1.90 A; A=1-147.
DR   PDB; 3FIT; X-ray; 2.40 A; A=1-147.
DR   PDB; 4FIT; X-ray; 2.50 A; A=1-147.
DR   PDB; 5FIT; X-ray; 2.30 A; A=1-147.
DR   PDB; 6FIT; X-ray; 2.60 A; A=1-147.
DR   PDBsum; 1FHI; -.
DR   PDBsum; 1FIT; -.
DR   PDBsum; 2FHI; -.
DR   PDBsum; 2FIT; -.
DR   PDBsum; 3FIT; -.
DR   PDBsum; 4FIT; -.
DR   PDBsum; 5FIT; -.
DR   PDBsum; 6FIT; -.
DR   ProteinModelPortal; P49789; -.
DR   SMR; P49789; -.
DR   BioGrid; 108563; 12.
DR   DIP; DIP-29947N; -.
DR   IntAct; P49789; 9.
DR   MINT; MINT-150697; -.
DR   STRING; 9606.ENSP00000342087; -.
DR   BindingDB; P49789; -.
DR   ChEMBL; CHEMBL1795151; -.
DR   DrugBank; DB02373; Adenosine Monotungstate.
DR   DrugBank; DB04389; Ado-P-Ch2-P-Ps-Ado.
DR   DrugBank; DB04173; Fructose.
DR   iPTMnet; P49789; -.
DR   PhosphoSitePlus; P49789; -.
DR   BioMuta; FHIT; -.
DR   DMDM; 1706794; -.
DR   EPD; P49789; -.
DR   PaxDb; P49789; -.
DR   PeptideAtlas; P49789; -.
DR   PRIDE; P49789; -.
DR   DNASU; 2272; -.
DR   Ensembl; ENST00000468189; ENSP00000417480; ENSG00000189283.
DR   Ensembl; ENST00000476844; ENSP00000417557; ENSG00000189283.
DR   Ensembl; ENST00000492590; ENSP00000418582; ENSG00000189283.
DR   GeneID; 2272; -.
DR   KEGG; hsa:2272; -.
DR   UCSC; uc003dkx.5; human.
DR   CTD; 2272; -.
DR   DisGeNET; 2272; -.
DR   GeneCards; FHIT; -.
DR   HGNC; HGNC:3701; FHIT.
DR   HPA; CAB002684; -.
DR   HPA; HPA018840; -.
DR   HPA; HPA018909; -.
DR   MalaCards; FHIT; -.
DR   MIM; 601153; gene.
DR   neXtProt; NX_P49789; -.
DR   OpenTargets; ENSG00000189283; -.
DR   Orphanet; 151; Familial renal cell carcinoma.
DR   PharmGKB; PA28140; -.
DR   eggNOG; KOG3379; Eukaryota.
DR   eggNOG; COG0537; LUCA.
DR   GeneTree; ENSGT00510000047967; -.
DR   HOGENOM; HOG000164170; -.
DR   HOVERGEN; HBG051614; -.
DR   KO; K01522; -.
DR   OMA; WANNDDI; -.
DR   OrthoDB; EOG091G0RR0; -.
DR   PhylomeDB; P49789; -.
DR   TreeFam; TF105432; -.
DR   BRENDA; 3.6.1.29; 2681.
DR   SABIO-RK; P49789; -.
DR   SIGNOR; P49789; -.
DR   ChiTaRS; FHIT; human.
DR   EvolutionaryTrace; P49789; -.
DR   GeneWiki; FHIT; -.
DR   GenomeRNAi; 2272; -.
DR   PRO; PR:P49789; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000189283; -.
DR   CleanEx; HS_FHIT; -.
DR   ExpressionAtlas; P49789; baseline and differential.
DR   Genevisible; P49789; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0047710; F:bis(5'-adenosyl)-triphosphatase activity; IDA:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0016787; F:hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0009117; P:nucleotide metabolic process; TAS:ProtInc.
DR   GO; GO:0006163; P:purine nucleotide metabolic process; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.30.428.10; -; 1.
DR   InterPro; IPR019808; Histidine_triad_CS.
DR   InterPro; IPR001310; Histidine_triad_HIT.
DR   InterPro; IPR011146; HIT-like.
DR   PANTHER; PTHR23089; PTHR23089; 1.
DR   Pfam; PF01230; HIT; 1.
DR   SUPFAM; SSF54197; SSF54197; 1.
DR   PROSITE; PS00892; HIT_1; 1.
DR   PROSITE; PS51084; HIT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Chromosomal rearrangement; Complete proteome;
KW   Cytoplasm; Hydrolase; Manganese; Mitochondrion; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation; Tumor suppressor.
FT   CHAIN         1    147       Bis(5'-adenosyl)-triphosphatase.
FT                                /FTId=PRO_0000109789.
FT   DOMAIN        2    109       HIT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00464}.
FT   NP_BIND      89     92       Substrate. {ECO:0000244|PDB:5FIT,
FT                                ECO:0000269|PubMed:9323207}.
FT   MOTIF        94     98       Histidine triad motif.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00464}.
FT   ACT_SITE     96     96       Tele-AMP-histidine intermediate.
FT                                {ECO:0000269|PubMed:15182206,
FT                                ECO:0000269|PubMed:9323207}.
FT   BINDING       8      8       Substrate. {ECO:0000244|PDB:3FIT,
FT                                ECO:0000269|PubMed:9261067}.
FT   BINDING      27     27       Substrate. {ECO:0000244|PDB:5FIT,
FT                                ECO:0000269|PubMed:9323207}.
FT   BINDING      83     83       Substrate. {ECO:0000244|PDB:5FIT,
FT                                ECO:0000269|PubMed:9323207}.
FT   BINDING      98     98       Substrate. {ECO:0000244|PDB:5FIT,
FT                                ECO:0000269|PubMed:9323207}.
FT   SITE        114    114       Important for induction of apoptosis.
FT   MOD_RES     114    114       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:15007172}.
FT   MOD_RES     145    145       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:15007172}.
FT   MUTAGEN      10     10       I->W: Strongly reduces affinity for
FT                                substrates and impairs apoptosis; when
FT                                associated with W-25.
FT                                {ECO:0000269|PubMed:12574506}.
FT   MUTAGEN      25     25       L->W: Reduces affinity for substrates and
FT                                impairs apoptosis. Strongly reduces
FT                                affinity for substrates and impairs
FT                                apoptosis; when associated with W-10.
FT                                {ECO:0000269|PubMed:12574506}.
FT   MUTAGEN      35     35       H->N: 50% decrease in catalytic activity.
FT                                No loss in substrate binding.
FT                                {ECO:0000269|PubMed:8794732}.
FT   MUTAGEN      94     94       H->N: 75% decrease in catalytic activity.
FT                                No loss in substrate binding.
FT                                {ECO:0000269|PubMed:8794732}.
FT   MUTAGEN      96     96       H->D: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:12574506,
FT                                ECO:0000269|PubMed:15182206,
FT                                ECO:0000269|PubMed:8794732,
FT                                ECO:0000269|PubMed:9576908}.
FT   MUTAGEN      96     96       H->G: Total loss of catalytic activity.
FT                                Rescuable with free imidazole.
FT                                {ECO:0000269|PubMed:12574506,
FT                                ECO:0000269|PubMed:15182206,
FT                                ECO:0000269|PubMed:8794732,
FT                                ECO:0000269|PubMed:9576908}.
FT   MUTAGEN      96     96       H->N: Total loss of catalytic activity.
FT                                No loss in substrate binding.
FT                                {ECO:0000269|PubMed:12574506,
FT                                ECO:0000269|PubMed:15182206,
FT                                ECO:0000269|PubMed:8794732,
FT                                ECO:0000269|PubMed:9576908}.
FT   MUTAGEN      98     98       H->N: 98% decrease in catalytic activity.
FT                                {ECO:0000269|PubMed:8794732}.
FT   MUTAGEN     114    114       Y->A: Impairs induction of apoptosis.
FT                                Strongly reduced affinity for substrates.
FT                                {ECO:0000269|PubMed:15007172,
FT                                ECO:0000269|PubMed:16407838}.
FT   MUTAGEN     114    114       Y->D: Impairs induction of apoptosis.
FT                                Reduces affinity for substrates.
FT                                {ECO:0000269|PubMed:15007172,
FT                                ECO:0000269|PubMed:16407838}.
FT   MUTAGEN     114    114       Y->F: Loss of phosphorylation by SRC.
FT                                Impairs induction of apoptosis.
FT                                {ECO:0000269|PubMed:15007172,
FT                                ECO:0000269|PubMed:16407838}.
FT   MUTAGEN     145    145       Y->F: No effect on phosphorylation by
FT                                SRC. {ECO:0000269|PubMed:15007172}.
FT   CONFLICT    146    146       F -> S (in Ref. 5; BAF82513).
FT                                {ECO:0000305}.
FT   STRAND        3      5       {ECO:0000244|PDB:1FIT}.
FT   STRAND        8     10       {ECO:0000244|PDB:1FIT}.
FT   HELIX        12     14       {ECO:0000244|PDB:1FIT}.
FT   STRAND       15     18       {ECO:0000244|PDB:1FIT}.
FT   STRAND       20     26       {ECO:0000244|PDB:1FIT}.
FT   STRAND       36     42       {ECO:0000244|PDB:1FIT}.
FT   HELIX        47     49       {ECO:0000244|PDB:1FIT}.
FT   HELIX        52     72       {ECO:0000244|PDB:1FIT}.
FT   STRAND       76     82       {ECO:0000244|PDB:1FIT}.
FT   HELIX        86     88       {ECO:0000244|PDB:1FIT}.
FT   STRAND       92     94       {ECO:0000244|PDB:1FIT}.
FT   STRAND       97    102       {ECO:0000244|PDB:1FIT}.
FT   HELIX       132    144       {ECO:0000244|PDB:1FIT}.
SQ   SEQUENCE   147 AA;  16858 MW;  14D85961A19ECF3E CRC64;
     MSFRFGQHLI KPSVVFLKTE LSFALVNRKP VVPGHVLVCP LRPVERFHDL RPDEVADLFQ
     TTQRVGTVVE KHFHGTSLTF SMQDGPEAGQ TVKHVHVHVL PRKAGDFHRN DSIYEELQKH
     DKEDFPASWR SEEEMAAEAA ALRVYFQ
//
